



Why take the test?

It is estimated that 5-10% of breast, ovarian and uterine cancer cases in the female population are due to a genetic predisposition. Prevention activities are essential for diagnosing cancers early and thereby creating a greater opportunity to administer effective treatment.

Who are they for?

These genetic tests are designed for physicians and their patients to confirm a clinical suspicion or to find any subjects at risk if there is a family history of cancer.

What do the tests detect?

The tests detect the presence of pathogenic variations in genes, which are explored using NGS sequencing.

Reliability

The tests have a sensitivity and specificity of at least 99%, and each variant detected is validated with additional technology.

99%

1



Blood sample collection

2



DNA extraction and gene sequencing

3



Bioinformatic analysis

4



Reports and results in 30 working days



Your solution provider in the world of genomics



© 2021 Personal Genomics Srl
The data and images are indicative and can be changed at any time without notice.

CLINICAL DIAGNOSTICS PREDICTIVE GENETIC TESTS FOR CANCER IN WOMEN

BREAST, OVARIAN AND ENDOMETRIAL
CANCER

Your solution provider in the world of genomics

NUMERO VERDE
800 589 057

✉ customercare@personalgenomics.it



Personal Genomics Srl
Via Roveggia, 43b
37136 Verona (VR) Italy
t +39 045 8202351
info@personalgenomics.it
www.personalgenomics.it

Biotechnology Division



SOLGROUP
a breath of life





We work alongside women to prevent cancer.

We offer genetic tests for the prevention of **breast, ovarian and endometrial cancer**, ensuring high quality standards at every stage of the data production and interpretation process.



BREAST AND/OR OVARIAN CANCER TESTS BRCA1 AND BRCA2 GENES

This genetic test is offered as a predictive test for breast and ovarian cancer. In 30-50% of these cases, the cause is an alteration in the two main genes, BRCA1 and BRCA2.

BREAST CANCER TEST SECOND LEVEL

This genetic test is recommended following a negative BRCA1 and BRCA2 gene analysis result.

BREAST CANCER TEST EXTENDED

The extended breast cancer test is the most comprehensive of the breast cancer tests offered. It also includes the analyses performed in the first (BRCA1 and BRCA2 genes) and second level tests.

.....

Variants in these genes are related to an increased risk of developing breast cancer and/or ovarian/Fallopian tube cancer. Indeed, breast cancer is the most common neoplasm in women, with an incidence of about 1 woman out of 8 (or 12%). Between 5 and 10% of them have a hereditary predisposition.

OVARIAN CANCER TEST

This genetic test is offered as a predictive test for ovarian cancer or to confirm a clinical suspicion in an already affected individual. In the general population, the incidence of ovarian cancer is 1 woman out of 75 (or 1.4%), and 15-20% of cases are due to hereditary predisposition.

ENDOMETRIAL CANCER TEST

This genetic test is offered as a predictive test for endometrial cancer or to confirm a clinical suspicion in an already affected individual. In the general population, the incidence of endometrial cancer (uterine cancer) is 1 woman out of 36 (or 2.8%), and 5-10% of these cases are due to hereditary predisposition.

